PTC Therapeutics

We extend our deepest gratitude to PTC Therapeutics for their sponsorship of INDConf LONDON 2025.

PTC Therapeutics, Inc (PTC) is a biopharmaceutical company focused on the discovery, development and commercialisation of clinically differentiated medicines that provide benefits to patients with rare disorders. Founded more than 25 years ago, PTC Therapeutics has successfully launched a number of rare disorder products and has a global commercial footprint. This success is the foundation that drives investment in a robust pipeline of potentially transformative medicines and PTC's mission to provide access to highly innovative treatments for patients who have a high unmet medical need.

PTC’s commitment to innovation and patient impact aligns perfectly with INDConf’s mission: bridging science and clinical care to transform the lives of those affected by rare neurological disorders.

Vitaflo International

We extend a warm thank you to Vitaflo International, a Nestlé Health Science company, for their invaluable support of the upcoming INDConf LONDON 2025.

Vitaflo has been a global leader in specialised medical nutrition for over 25 years, developing clinically backed medical foods for inherited metabolic disorders, paediatric kidney disease, and ketogenic diets.

Their patient-centered approach includes innovations such as Ready to feed products for the dietary management of IEM and unique medical foods for the dietary management of Glycogen storage disease and drug-resistant epilepsy.

By ensuring consistent quality, accessibility, and education through resources like the VIA portal, Vitaflo empowers patients and healthcare providers across more than 70 countries.

Their clinical evidence-based solutions align perfectly with INDConf’s mission to
bridge science and patient care.

Neurometabolic Unit - UCLH/National Hospital for Neurology & Neurosurgery

A huge thank you to the Neurometabolic Unit at UCLH/National Hospital for Neurology and Neurosurgery (Queen Square) for their invaluable support of INDConf LONDON 2025.

Since 1995, this UKAS-accredited laboratory has provided clinically essential testing and translational research in mitochondrial, neurotransmitter, pterin, and amino acid disorders.

Their recent advances include: 

• A multiplexed LC‑MS method for CSF neurotransmitter and 5-methyltetrahydrofolate and related metabolites, validated by Dr Simon Pope 
• Innovative uHPLC‑QDa mass spectrometry for plasma amino acid profiling—advancing precision diagnostics in alignment with UKAS accreditation 
• Important partnerships, such as the 2025 collaboration with Guilford Street Labs, bringing AI-driven, next-gen diagnostics to neurotransmitter and mitochondrial disorders.

Based in the heart of Queen Square, the Unit exemplifies bench-to-bedside excellence, integrating top-tier science into patient care—a mission perfectly aligned with INDConf’s goals.

Chan Zukerberg Initiative

We’re honoured to acknowledge the Chan Zuckerberg Initiative (CZI) for their generous grant to Hrabriša – Lil’ Brave One through the “Rare as One” Network — marking one of only five patient-led initiatives outside North America to receive this global support.

CZI empowers parent-led rare disease groups to actively participate in scientific research and community-led projects. Thanks to their backing, Hrabriša is amplifying access to early diagnosis, care, and education in non-English-speaking communities affected by congenital neurotransmitter disorders.

This partnership fuels our shared mission to translate patient voices into scientific impact, advancing awareness, research, and global health equity.

We’re proud to be driving this movement alongside CZI and Hrabriša.

Guilford Street Laboratories

Guilford Street Laboratories (GSL), a University College London spin-out (founded in 2023), is transforming rare disease diagnostics with machine learning-enhanced mass spectrometry.

Speed + Precision:
Specialised protein, lipid, and metabolite assays deliver highly sensitive and accurate biomarker data for early disease detection and therapeutic monitoring.

End-to-End Expertise:
From academic research origins to a clinical-stage lab, GSL collaborates with hospitals, industry partners, and EU consortiums to bring advanced diagnostics to the frontline.

Innovation Milestones:
Their next-gen AI-enabled assays, like PD Predict and HCM Predict, have earned FDA Breakthrough Designation, marking a significant advance in blood-based diagnostics for Parkinson’s and cardiomyopathies.

Why it matters to INDConf delegates:
GSL represents the cutting edge of bench-to-bedside translation, empowering clinicians and researchers with tools that support early detection, patient stratification, and personalised intervention.